Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000, with Q4 revenue at $49.9 million, representing an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [8][20] - Adjusted EBITDA for Q4 was positive at $536,000, marking a significant improvement of approximately $11 million sequentially from Q3, and the first return to positive adjusted EBITDA in four quarters [9][22] - GAAP net loss for Q4 was $63 million, including a $25.8 million non-cash impairment charge, compared to a loss of $46.1 million in Q4 2024 [21] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% when excluding the prior year's CleanCap revenue [20][25] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [20][26] - For the full year, TriLink revenue was $119.8 million, while Cygnus revenue increased 5% to $66 million [25][26] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [21] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809 from 643 a year ago, indicating sustained interest in RNA-based approaches [17] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, increase customer interaction, and deliver better financial results, with a focus on expanding TriLink's role in the mRNA and gene-based therapeutic workflow [7][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing stabilization in the broader tools and biotech environment, with signs of recovery in biopharma funding [16] - The company anticipates total revenue growth of 8%-13% in 2026, with adjusted EBITDA expected to improve by $50 million-$52 million over 2025 [27][28] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [29] - The securities class action lawsuits against the company were dismissed, reflecting positive progress in resolving legal matters [30] Q&A Session Summary Question: Visibility on order volume and growth areas - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating strong customer engagement [34][35] Question: Gross margin expansion details - The gross margin expansion of 1,200 basis points is attributed to $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [41] Question: AI's role in efficiency - The company is utilizing AI through its mRNA Builder platform, which automates the design of optimized RNA constructs, enhancing customer engagement [43] Question: Expectations for 2026 and potential challenges - Management remains optimistic for Q1 and the year, with no significant negative comps expected, and strong customer spending observed [47][50] Question: COVID CleanCap revenue expectations - The company expects $10 million-$20 million in COVID CleanCap revenue for the first half of 2026, with no additional revenue anticipated in the second half [92][94]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000. Total Q4 revenue was $49.9 million, with an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [8][20] - Adjusted EBITDA for Q4 was positive at $536,000, marking a significant improvement of approximately $11 million sequentially from Q3, and the first return to positive adjusted EBITDA in four quarters [9][22] - GAAP net loss before non-controlling interest for Q4 was $63 million, compared to a loss of $46.1 million in Q4 2024 [21] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% year-over-year when excluding the prior year's COVID CleanCap comparison [20][25] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [20][26] - For the full year, TriLink revenue was $119.8 million, or 64% of total revenue, while Cygnus revenue increased 5% to $66 million [25][26] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [21] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809, up from 643 a year ago, indicating sustained interest in RNA-based approaches [17] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, increase customer interaction, and deliver better financial results, with a focus on expanding TriLink's role in the mRNA and gene-based therapeutic workflow [7][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [13][14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing stabilization in the broader tools and biotech environment, with signs of recovery in biopharma funding [16][18] - The company anticipates total revenue growth of 8%-13% in 2026, with adjusted EBITDA expected to improve by $50 million-$52 million over 2025 [27][28] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [29] - The securities class action lawsuits against the company and certain former executives were dismissed in full [30] Q&A Session Summary Question: Visibility on order volume and growth areas - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating strong customer engagement [33][35] Question: Gross margin expansion details - The gross margin expansion of 1,200 basis points is attributed to $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [41] Question: AI's role in drug discovery and efficiency - The company is utilizing AI through its mRNA Builder platform, which automates the design of optimized RNA constructs, enhancing efficiency in customer workflows [43] Question: Revenue guidance and potential seasonality - Management expressed optimism for Q1, indicating no serious negative comps and a diverse set of customers driving orders [47][50] Question: COVID CleanCap revenue expectations - The company expects $10 million-$20 million in COVID CleanCap revenue for the first half of 2026, with no additional revenue anticipated in the second half [92][94] Question: Traction in new product lines - The ModTail technology has seen strong early adoption, generating over $1 million in orders, and the company plans to launch more kits in 2026 [98]

Financial Data and Key Metrics Changes - The company reported full-year revenue of $185.7 million, exceeding guidance by approximately $700,000. Total Q4 revenue was $49.9 million, with an 18% year-over-year growth when excluding $14.3 million from high-volume CleanCap sales in Q4 2024 [6][19] - Adjusted EBITDA for Q4 was positive at $536,000, marking the first return to positive adjusted EBITDA in four quarters, an improvement of approximately $11 million sequentially from Q3 [7][21] - GAAP net loss before non-controlling interest for Q4 was $63 million, compared to a loss of $46.1 million in Q4 2024 [20] Business Line Data and Key Metrics Changes - TriLink generated $34.6 million in revenue for Q4, down 17% year-over-year, but base revenue grew 25% year-over-year when excluding the prior year's COVID CleanCap revenue [19][24] - Cygnus revenue was $15.3 million in Q4, up 4% year-over-year, driven by demand for HCP kits [19][25] - For the full year, TriLink revenue was $119.8 million, while Cygnus revenue increased 5% to $66 million [24][25] Market Data and Key Metrics Changes - Revenue by geography in Q4 was 55% from North America, 15% from EMEA, 21% from Asia Pacific (excluding China), 8% from China, and 1% from Latin and Central America [20] - The number of companies pursuing mRNA and guide RNA programs globally increased to 809, up from 643 a year ago, indicating sustained interest in RNA-based approaches [15] Company Strategy and Development Direction - The company aims to simplify operations, improve execution, and enhance customer engagement, positioning TriLink as a key player in the mRNA and gene-based therapeutic workflow [6][10] - Investments are prioritized in high-return opportunities across mRNA, cell and gene therapy, and biologic safety testing, with a robust pipeline of new product introductions planned for 2026 [12][14] - The company is focused on operational discipline and cost-saving measures, exceeding initial targets and positioning for revenue growth and positive cash flow in 2026 [8][26] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism for 2026, citing improved visibility and strong order volumes, particularly in GMP consumables and larger orders in Discovery [14][34] - The broader biotech environment appears to be stabilizing, with signs of recovery in biopharma funding, although smaller players remain cautious [14][16] - Customer feedback indicates a constructive FDA stance in areas like cell and gene therapy, which is expected to support ongoing program advancements [17] Other Important Information - The company completed the implementation of its remediation plan to address previously identified material weaknesses in internal controls [28] - The securities class action lawsuits against the company and certain former executives were dismissed in full [29] Q&A Session Summary Question: Visibility and order volume tracking for 2026 - Management noted that order volumes are materially higher than the previous year, particularly in GMP consumables and larger orders in Discovery, indicating confidence in forecasts for the year [33][34] Question: Demand factors for GMP consumables - Growth in GMP consumables is attributed to a broad set of customers rather than a single program, reflecting a diverse customer base [35][36] Question: Gross margin expansion details - Gross margin expansion of 1,200 basis points is driven by $65 million in annualized cost savings and improved product mix, particularly from GMP consumables [39] Question: Current mRNA pipeline trends - Management estimates about a third market share in the mRNA ecosystem, with growth expected as more programs transition from discovery to GMP [60][64] Question: COVID CleanCap revenue expectations - The company expects total COVID CleanCap revenue of $10 million-$20 million for 2026, all anticipated in the first half of the year [91][93]

Financial Data and Key Metrics Changes - The company reported fourth quarter revenues of $57 million, aligning with expectations, and full year revenues of $259 million, near the midpoint of the previously stated range of $255 million to $265 million [12][13] - GAAP net loss before non-controlling interests was $46 million for Q4 2024, compared to a loss of $110 million in Q4 2023, while the full year net loss was $260 million, up from $138 million in 2023 [15][16] - Adjusted EBITDA for Q4 2024 was a negative $1 million, down from $21 million in Q4 2023, with full year adjusted EBITDA at $36 million, reflecting a margin of 14% [15][17] Business Line Data and Key Metrics Changes - The biologic safety testing segment generated $15 million in Q4 and $63 million for the full year, with an adjusted EBITDA margin of about 70% [12][24] - The nucleic acid production segment had revenues of $42 million in Q4, including $14 million from high-volume CleanCap, and full year revenues of $196 million with an adjusted EBITDA margin of 26% [13][23] Market Data and Key Metrics Changes - Revenue breakdown by customer type for 2024 showed 48% from biopharma, 25% from life science and diagnostics, and 18% through distributors [14] - The company reported $13.6 million in revenue from China for the full year, with expectations for flat growth in 2025 [98][100] Company Strategy and Development Direction - The company is focused on returning its base business to growth, projecting revenues of $185 million to $205 million for 2025, excluding high-volume CleanCap [27][30] - Strategic investments include expanding commercial footprint and intellectual property protection while managing costs [31][45] - Recent acquisitions are expected to enhance capabilities in DNA and RNA design and discovery, positioning the company for future growth [48][62] Management's Comments on Operating Environment and Future Outlook - Management acknowledged challenges in forecasting due to market dynamics but expressed confidence in the company's assets and growth potential [25][26] - The company is enhancing visibility into customer clinical programs to improve sales forecasting accuracy [42][53] Other Important Information - The company ended 2024 with $322 million in cash and $300 million in long-term debt, resulting in a net cash position of $22 million [18][19] - Capital expenditures for 2024 were $30 million, with expectations for a decline to $15 million to $20 million in 2025 [20][33] Q&A Session Summary Question: Can you provide insights on profitability and gross margins for 2025? - Management indicated that the cost structure for 2025 will remain consistent with 2024, with fixed costs around $200 million and variable costs ranging between 10% and 12% [66][68] Question: How is the company improving visibility with key customers? - Management noted that new agreements include mandatory disclosure requirements for clinical trial milestones, which should enhance visibility [75][77] Question: What are the expectations for segment growth and market assumptions? - Management expects Q1 revenues to be slightly up from Q4 2024, with growth driven by GMP programs and the integration of recent acquisitions [80][83] Question: What are the capital allocation priorities for 2025? - The company plans to focus on reducing cash interest expenses and is open to M&A opportunities that align with their strategic goals [88][90] Question: How does the company view its exposure to NIH funding changes and growth in China? - Management does not anticipate significant headwinds from NIH funding changes and expects flat growth in China for 2025 [97][100]